Emergence of carbapenem resistance due to porin loss in an extended-spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae strain during meropenem therapy.
Webster
D P
DP
Gaulton
T
T
Woodford
N
N
Pike
R
R
Turton
J
J
Perry
C
C
Bowler
I C J W
IC
D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use*; D001426:Bacterial Proteins / Q000235:genetics / Q000302:isolation & purification; D015780:Carbapenems / Q000378:metabolism / Q000494:pharmacology*; D004591:Electrophoresis, Polyacrylamide Gel; D006801:Humans; D007710:Klebsiella Infections / Q000188:drug therapy* / Q000382:microbiology; D007711:Klebsiella pneumoniae / Q000737:chemistry / Q000187:drug effects* / Q000201:enzymology / Q000302:isolation & purification; D008297:Male; D000077731:Meropenem; D008875:Middle Aged; D018272:Porins / Q000235:genetics* / Q000302:isolation & purification; D013845:Thienamycins / Q000627:therapeutic use*; D018440:beta-Lactam Resistance; D001618:beta-Lactamases / Q000096:biosynthesis
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D015780:Carbapenems; D018272:Porins; D013845:Thienamycins; D001618:beta-Lactamases; D000077731:Meropenem